key: cord-0769261-fow0f0nq
authors: Jiménez, David; García-Sanchez, Aldara; Rali, Parth; Muriel, Alfonso; Bikdeli, Behnood; Ruiz-Artacho, Pedro; Le Mao, Raphael; Rodríguez, Carmen; Hunt, Beverley J.; Monreal, Manuel
title: Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis
date: 2020-11-17
journal: Chest
DOI: 10.1016/j.chest.2020.11.005
sha: 6b656d1c233774782cbf4a02a112c1b82a81d972
doc_id: 769261
cord_uid: fow0f0nq

Background Individual studies have reported widely variable rates for venous thromboembolism (VTE) and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19). Research question What is the incidence of VTE and bleeding among hospitalized patients with COVID-19? Methods In this systematic review and meta-analysis we searched 15 standard and COVID-19 specific sources between January 1, 2020 and July 31, 2020, with no restriction by language. We pooled incidence estimates using random-effects meta-analyses. We evaluated heterogeneity using the I2 statistic. We assessed publication bias using Begg's and Egger's tests. Results The pooled incidence was 17.0% (95% confidence interval [CI], 13.4%-20.9%) for VTE, 12.1% (95% CI, 8.4%-16.4%) for DVT, 7.1% (95% CI, 5.3%-9.1%) for PE, 7.8% (95% CI, 2.6%-15.3%) for bleeding, and 3.9% (95% CI, 1.2%-7.9%) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed by screening (33.1% vs. 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs. 7.1% in the ward), in prospective studies (25.5% vs. 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%). Interpretation Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT and subsegmental PE, in critically ill patients, and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants, and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes.

, a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in substantial respiratory pathology and also causes important manifestations outside the pulmonary parenchyma (1, 2) . COVID-19 may predispose patients to venous thromboembolic events (deep vein thrombosis [DVT] and/or pulmonary embolism [PE] ), due to hypoxia, excessive inflammation, platelet activation, endothelial dysfunction, and stasis (3) . Accumulating evidence suggests that hospitalized patients with COVID-19 may have a high incidence of venous thromboembolism (VTE), including those receiving standard thromboprophylaxis according to guidelines for acutely ill medical patients (4) (5) (6) (7) .

However, an accurate estimate of the incidence of VTE in hospitalized patients diagnosed with COVID-19 remains unclear, with incidence rates reported between 4.8% and 85% (5, (8) (9) (10) (11) . This variability might have been influenced by the type of events counted, the type of testing for VTE, assessment setting, and the use and type of thromboprophylaxis. Furthermore, the assessment of PE in patients with COVID-19 is conflated by the presence of immunothrombosis (12) . It is likely that in some patients with COVID-19, local inflammation in the lungs with subsequent endothelial inflammation, complement activation, thrombin generation, platelet and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate into in-situ small pulmonary vessel thrombosis (12) .

In addition to an increased risk of thrombosis, patients with COVID-19 might be at risk of excess bleeding due to factors such as imbalances in platelet production and destruction, coagulation factor consumption in the setting of severe inflammation, and use of antiplatelet or anticoagulant agents (13) . A recent retrospective study included 144 critically ill patients primarily receiving standard-dose prophylactic anticoagulation and found a major bleeding event rate of 5.6% (14) .

Comprehensive assessment of the thrombotic and hemorrhagic event rates is critical in thorough assessment of the disease course for COVID-19 and for considering J o u r n a l P r e -p r o o f strategies to mitigate patient outcomes. Therefore, we sought to conduct a comprehensive systematic review and meta-analysis to assess the overall incidence of VTE and bleeding among hospitalized patients with COVID-19.

We prospectively submitted the systematic review protocol for registration on PROSPERO (CRD42020198864; e-Appendix 1). We have followed the Reporting Checklist for Meta-analyses of Observational Studies (MOOSE) (15) to conduct and report this systematic review (e- Table 1 ).

From January 1, 2020 to July 31, 2020, we included observational studies such as cohort and cross-sectional studies in any geographical area evaluating the incidence of VTE and/or bleeding among hospitalized patients with WHO-defined confirmed or probable COVID-19. We excluded studies enrolling <10 consecutive patients initially hospitalized for COVID-19. Overview of the Evidence platform), EPPI Centre living systematic map of the evidence, and reference lists of included papers, We hand searched preprint servers (bioRxiv, medRxiv, and Social Science Research Network First Look) and coronavirus resource centres of The Lancet, JAMA, and N Engl J Med (e-Appendix 2). We did not limit our search by language. The search strategy is available in e-Appendix 2.

We screened titles and abstracts, reviewed full texts, extracted data, and assessed risk of bias by two authors (DJ and AG-S) and independently, using standardized prepiloted J o u r n a l P r e -p r o o f forms. We resolved disagreements by discussion within the wider team (PR, BB and MM).

The primary outcome was the incidence of non-fatal or fatal VTE during hospitalization for COVID-19, expressed as the proportion of patients with a diagnosis of VTE. VTE included upper and lower limb DVT and PE diagnosed by accepted imaging tests, either after clinical suspicion or by routine screening. The secondary outcome was the incidence of bleeding during hospitalization for COVID-19. We also determined the incidence of major bleeding (including fatal bleeds). Definitions of major bleeding were according to definitions in the individual studies. The outcomes data from the first available time point identified as a primary endpoint from each study were incorporated into our primary analysis.

Because of high heterogeneity (as expected and observed), we analyzed pooled data on the incidence of VTE and major bleeding by using a random-effects (DerSimonian and Laird method) model approach. We measured statistical heterogeneity using the Higgins I 2 statistic (16, 17) . We used the Newcastle-Ottawa scale to rate risk of bias for comparative non-randomised studies corresponding to every study's design (cohort or cross-sectional) (18, 19) . The Begg rank correlation method assessed for publication bias.

We analyzed data for subgroup effects by VTE type (i.e., DVT vs. PE), as well as 

We did two sensitivity analyses to test the robustness of our findings. First, we analyzed outcomes from the longest available follow-up points in studies reporting outcomes at multiple time points to ensure no significant changes in outcome estimates. Second, we ran supplemental analyses with inverse variance fixed-effects models. We did analyses using Stata version 14.2 (Stata).

The searches yielded 10,141 citations. After we removed duplicates and reviewed the titles and abstracts, 9889 articles were excluded. Of the remaining 252 studies, 203 were excluded after reviewing the full text manuscript. A total of 49 studies reporting the incidence of venous thrombosis (n =44), bleeding (n =1), or both (n =4) were included in the review (4, 5, (8) (9) (10) (11) . Two studies included overlapping patient populations (5, 39) , and only outcomes data from the first publication were considered for the analyses ( Figure 1 ).

This review is based on a pooled sample of 18,093 patients with reported information related to VTE, 1,273 of whom experienced a VTE event (47 studies) (4, 5, 8-11, 20-37, 39-51) , and a pooled sample of 1,411 patients with reported information related to bleeding, 148 of whom experienced a bleeding event (5 studies) (8, 36, 50, 51, 60) . The sample sizes ranged widely across studies (median 108 patients, range 10-1,477).

Among the 47 studies that reported information related to VTE, 8 (17%) were conducted in the US (8, 22, 37, 39, 43, 48, 50, 59) , 32 (68%) in Europe (4, 5, 10, 11, 20, 21, 23, J o u r n a l P r e -p r o o f 26, 28-36, 40-42, 44, 46, 47, 49, 52-58, 61) , and 7 (15%) elsewhere (9, 24, 25, 27, 45, 60, 62) . The most common study design was retrospective (33/47; 70%) (4, 8, 10, 11, 20-25, 27, 29-32, 34, 35, 37, 39-41, 43-46, 48, 50, 54-56, 58-60) , followed by prospective (10; 21%) (5, 28, 36, 42, 47, 49, 52, 53, 57, 61) , and cross-sectional (n =4; 9%) (9, 26, 33, 62) . Twenty-one studies (20/47; 43%) were conducted exclusively in the ICU setting (4, 5, 9, 10, 21, 25, 27, 29, 32, 35-37, 40, 42, 43, 49, 55, 57, 59, 61, 62) , whereas 10 studies (23%) only enrolled patients in the ward setting (20, 23, 28, 30, 31, 44, 46, 47, 53, 56) ( Table 1) . None of the studies identified by this systematic review had VTE and bleeding events independently adjudicated.

The mean age was consistently between 52 and 71 years. The proportion of males ranged from 46% to 81%. Approximately 0% to 12% patients had a history of VTE, and up to 24% of patients had cancer. The follow-up duration varied from 2 to 55 days (e- (4, 5, 8, 10, 21, 22, 24, 27, 29-32, 34-37, 39, 41, 43, 45, 46, 48, 50, 52, 54-56, 58, 59) ; and 5 studies combined both modalities to assess for VTE (11, 20, 23, 42, 60) ( Table 1) .

The Newcastle Ottawa scores for the studies ranged from four to nine (maximum 9, a higher score indicating a lower risk of bias). Twenty-eight studies (57%) scored eight or above and were considered to be at low risk of bias (8, 10, 11, 20, 23, 25, 28-33, 36, 40-43, 45, 48-53, 56, 57, 60, 62) (see full assessment in e- Table 3 ). Table 2 gives the results of overall and subgroup meta-analyses. Estimates for the population-based studies ranged from 0% to 85.4% (Figure 2) , and the random-effects overall pooled estimated incidence of VTE was 17.0% (95% CI, 13.4%-20.9%), with high heterogeneity (I 2 =97%; P <0.001). e- Figure 1 shows some evidence of publication bias as indicated by visual inspections of the funnel plots and by the Egger test for small study effects for the primary outcome (bias coefficient for the main analysis -0.003; 95% CI, -0.001 to -0.004; P =0.001). Table 2 gives the results of overall and subgroup meta-analyses. Estimates for the population-based studies ranged from 2.7% to 21.6% (Figure 3) , and the randomeffects overall pooled estimated incidence of bleeding was 7.8% (95% CI, 2.6%-15.3%), with high heterogeneity (I 2 =95%; P <0.001). No publication bias was found based on the funnel plot, Egger test (bias coefficient for the main analysis -2.83; 95% CI, -11.88 to 6.22; P =0.39), and Begg test (P =1.0) (e- Figure 1 ).

We ran separate meta-analyses according to the type of VTE (i.e., DVT vs. PE) ( Table   2 and e- Figure 2) . The graph shows that the incidence of DVT (36 studies; n =11,566) was 12.1%, while the incidence of PE (32 studies; n =13,424) was 7.1%.

A setting difference in the incidence of VTE was observed between the studies identified in the systematic review. Forty-one studies separately reported the number of ward and ICU patients with and without VTE. The pooled incidence of VTE was 7.1% for patients admitted to the ward and 27.9% for those admitted to the ICU (e- Table 3) .

When the studies were categorized by different diagnostic methods of VTE (i.e., screening vs. clinical diagnosis), significantly different pooled proportions of VTE were found among different subgroups (Table 2 and e-Figure 2) . Eighteen of the studies J o u r n a l P r e -p r o o f diagnosing VTE were based on screening (n =1,067), and the combined incidence estimate of VTE was 33.1%. Thirty-four studies were based on clinical diagnosis (n =17,122), and the incidence estimate of VTE was 9.8%.

When the studies were categorized by different intensity of thromboprophylaxis (no pharmacological thromboprophylaxis vs. standard-dose thromboprophylaxis vs.

proportions of VTE were found among different subgroups (Table 2 and e-Figure 2) . In 4 studies, less than 40% of the patients received pharmacological prophylaxis (n =382), and the combined incidence estimate of VTE was 21.0%. In 19 studies, more than 70% of the patients received standard dose prophylaxis (n =7,008), and the combined incidence estimate of VTE was 18.2%. For the 8 studies in which patients received intermediate-dose thromboprophylaxis or therapeutic anticoagulation (n =1549) (11, 21, 26, 32, 40, 41, 50, 56) , the combined incidence estimate of VTE was 19.4%.

Most of the studies were from Europe (n =8,340), only 8 were from North America (n =8,014), and 7 were from Asia (n = 1,739). The incidence of VTE was 17.9% in Europe, 9 .5% in North America, and 23.7% in Asia ( Table 2 and e- Figure 2) . e- Table 4 shows subgroup meta-analyses according to the geographical area.

After excluding patients with a diagnosis of CAT/IDDVT, the combined incidence estimate of DVT was 6.2%. The pooled incidence of PE was 5.5% when patients with ISSPEs were excluded from the analyses.

The pooled incidence of major bleeding was 3.9%. The highest pooled incidence estimate of any bleeding was reported for patients receiving intermediate-or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%) ( Table 2 ). e- Figure 2 presents the forest plot of the incidence of bleeding across subgroups of patients.

When we analyzed outcomes from the longest available follow-up points in studies reporting outcomes at multiple time points, the pooled incidence of VTE was 18.0%. We reconsidered our findings using inverse variance fixed-effects meta-analysis (e- Figure   3 ). The combined incidence estimate of VTE was 4.7%, while the incidence of bleeding was 9.4%.

This comprehensive systematic review and meta-analysis from several countries and hospital systems showed that the overall incidence rate of VTE among hospitalized patients with COVID-19 was 17.3%, with roughly two third of the events being DVTs.

The results were sensitive to type of assessment for VTE, type of VTE, setting of hospitalization and nature of data collection, with higher rates with routine screening, inclusion of CAT/IDDVT and ISSPE, in critically ill patients, and in prospective studies.

In turn, bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants, and nature of data collection. Event rates both for VTE and for bleeding are clinically relevant and deserve urgent attention for assessment of the clinical significance and strategies to improve outcomes.

Due the concerns related to thrombotic events, multiple individual studies had reported the rates of VTE in patients with COVID-19. The main strength of this study is to provide an aggregate estimate. We are cautious not to be overly certain in the precise quantitative estimates of effects, although the qualitative effect and direction is probably of high certainty. Some of the variations across the studies, as shown in our pooled estimates, might be explained by the differences in endpoint definition, testing strategies, and patients baseline risk. Studies that used broader endpoint definitions (such as inclusion of ISSPEs and CAT/IDDVTs) typically reported higher event rates.

Systematic screening is also known to increase the diagnostic yield for detecting VTE (63) . Similarly, ICU stay has been previously shown to be a marker of high risk for VTE (64) . The lower rates of VTE in retrospective studies, many of which were from the US, A critical unresolved question is whether all these VTE events, if any, correlate with mortality. Analyses from large observational studies will be informative in this regard. It should be specifically determined if events such as ISSPE, which in many cases may reflect immunothrombosis, or IDDVT, carry prognostic significance. This is particularly important considering that the bleeding events are not rare in patients with COVID-19 and will likely increase as a result of intensified antithrombotic therapy.

From a practical perspective, it is important to identify optimal strategies to avoid deterioration and thrombotic events across the spectrum of patients with COVID-19, including outpatients, inpatients in medical wards, and critically-ill patients. In this context, results from several ongoing randomized trials will be informative (65) . These studies can indicate whether more intense antithrombotic therapy can reduce the rates of VTE, but also mortality, which may be driven by VTE as well as microangiopathic thrombotic events and arterial thrombosis.

Studies included in this systematic review found a large proportion of patients with COVID-19 who had isolated distal DVT, catheter-associated thrombosis and subsegmental PE, supporting the notion that the severe inflammatory response and thromboinflammation may have contributed to such events (66) . Although our metaanalysis was not designed to assess treatment efficacy, future studies should determine if immunomodulatory therapies may confer benefit to reduce both the rates of thrombotic events and mortality (67) . In this context, reporting of the thrombotic event rates from the trials testing immunomodulatory therapies, including RECOVERY (68), , and others (69) will be highly awaited.

While the main purpose of this study was to report on the epidemiology, rather than comparative effectiveness of health interventions, we did not find an association J o u r n a l P r e -p r o o f between the intensity of thromboprophylaxis and the rate of thrombotic events and yet, the rate of clinically relevant bleeding complications among patients who received intermediate-or full-dose anticoagulation exceeded that recorded among those treated with preventive doses. Therefore, results from the ongoing randomized clinical trials are necessary to determine the optimal dose and course of thromboprophylaxis in patients with COVID-19 (65, 70) .

This study has several limitations. First, in the absence of individual patient data, we were unable to perform a detailed assessment of subgroups or to conduct time-to-event analyses. Second, missing or unreported data in individual studies limited the inferences from aggregate estimates for some of the outcomes. In addition, lack of independent adjudication might have introduced significant biases into this metaanalysis's estimates of the incidence of VTE and bleeding among hospitalized patients with COVID-19. Third, this study did not assess the arterial thrombotic events. The existing literature indicates that the majority of thrombotic events in patients with COVID-19 are in the venous circulation (3). Fourth, the risk of bias tool that we assessed may have not captured all the potential, methodological limitations of the included studies. It should be noted that prospective, preferentially multicenter and international studies with prospective data collection and similar criteria for outcome assessment will be preferred to provide balanced estimates for disease incidence. Fifth, we were unable to explore the extent of association between incident thrombotic or hemorrhagic events and all-cause mortality. Finally, the high statistical heterogeneity in our study suggests that differences in prevalence estimates across the included studies were determined by factors such as differences in baseline characteristics and baseline risk of VTE, frequency and type of imaging modalities to assess for VTE, setting of hospitalization and acuity of illness, and thromboprophylactic regimens such as type, dose, and duration of antithrombotic therapy. The large difference in results between the random-effects and the fixed-effects models provides a useful description of the importance of heterogeneity in the individual estimates of included studies, and it is for this reason that we had pre-specified to use random-effects models for the primary analyses. In addition, small studies might have accounted for this difference (71) , and J o u r n a l P r e -p r o o f we encourage an updated analysis of incidence rates once several other large-scale studies become available.

In this systematic review and meta-analysis, nearly one in six hospitalized patients with COVID-19 had incident VTE, although the results were sensitive to hospitalization setting, mode of VTE diagnosis, and outcome definitions across studies, while the rates of major bleeding were much lower, but sensitive to use of escalated doses of anticoagulants. Additional studies are required to understand the utility of more potent antithrombotic or immunomodulatory therapies to safely mitigate the risk of thrombotic events, and mortality. J o u r n a l P r e -p r o o f

COVID-19 and multiorgan response

Extrapulmonary manifestations of COVID-19

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Lille ICU Haemostasis COVID-19 group. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Presenting characteristics, treatment patterns and outcomes among patients with Venous Thromboembolism during hospitalisation for COVID-19

Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report

COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection

Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom

Incidence of venous thromboembolism in hospitalized patients with COVID-19

The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications

COVID-19-associated coagulopathy: an exploration of mechanisms

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

Quantifying heterogeneity in a meta-analysis

Measuring inconsistency in meta-analyses

No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2

Thrombosis in hospitalized patients with COVID-19 in a New York City Health System

Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?

Characteristics of acute pulmonary embolism in patients with COVID-19 associated pneumonia from the city of Wuhan

DVT incidence and risk factors in critically ill patients with COVID 19

Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom

Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019

Critical Covid-19 France Investigators. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Systematic screening for venous thromboembolic events in COVID-19 pneumonia

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Severe pulmonary embolism in COVID-19 patients: a call for increased awareness

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Prevalence of venous thromboembolism in critically ill patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis

Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019

Non-overt coagulopathy in non-ICU patients with mild to moderate COVID-19 pneumonia

Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients

Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis

High rate of pulmonary thromboembolism in patients with SARS-CoV-2 pneumonia

ICU patients with COVID-19. Chest. In press

Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19)

Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19

The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience

Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19

GEMELLI AGAINST COVID-19 Group. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis

Thrombotic risk in COVID-19: a case series and case-control study

Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening

Venous thromboembolism in noncritically ill patients with COVID-19 infection

High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients

Pulmonary embolism in hospitalised patients with COVID-19

Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection

Risk assessment of venous thromboembolism and bleeding in COVID-19 patients

Increased risk of deep vein thrombosis in intensive care unit patients with CoViD-19 infections? -Preliminary data

Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China. Prevalence, risk factors, and outcome

Screening and diagnosis of VTE: the more you look, the more you find?

Venous thromboembolism prophylaxis in critically ill patients

Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies

Thromboinflammation and the hypercoagulability of COVID-19

Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research

Dexamethasone in hospitalized patients with Covid-19 -preliminary report

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Meta-analysis: pitfalls and hints

J o u r n a l P r e -p r o o f